Ardelyx announced on July 2, 2024, its decision not to apply for the Transitional Drug Add-on Payment Adjustment (TDAPA) for XPHOZAH. This strategic choice was made to preserve shared decision-making between patients and healthcare providers regarding treatment options.
The company's decision means XPHOZAH will not be eligible for the additional payment adjustment, which could impact its reimbursement landscape. This move is part of Ardelyx's broader strategy to ensure patient access to XPHOZAH without protocols that might limit provider and patient autonomy.
This development has significant implications for XPHOZAH's commercialization, particularly concerning its revenue potential from Medicare beneficiaries. The company continues to support legislative efforts, such as the Kidney Patient Act, to address reimbursement challenges.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.